Physician

Kevin B. Kim, M.D.

According to 2025 Medicare claims, Kevin Kim, M.D. (NPI: 1851485056) practices hematology/oncology in the San Francisco-San Mateo-Redwood City, CA market, with the plurality of this provider's patient population coming from San Francisco, CA. This provider's primary affiliated billing organization is SAN FRANCISCO ONCOLOGY ASSOCIATES MEDICAL GROUP INC (NPI: 1457385379; TIN: 943255519) and primary practice location at 94115-2378. Kim is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), Main Street Rural Health Sycamore ACO LLC (ACO ID: A5403), and APA ACO Inc. (ACO ID: D0215), participating under both the MSSP and REACH models.

Kim's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 239 traditional Medicare patients, billed 63,107 HCPCS/CPT codes, and received $2,475,761 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 622 prescription claims across 84 beneficiaries totaling $2,330,790 in drug costs, led by Tagrisso (Osimertinib Mesylate). DME data shows 15 claims. Open Payments data shows 138 records totaling $1,649,777. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,160,650 to $2,330,790. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	182	56,892	$2,174,119
2016	183	63,617	$2,207,115
2017	187	59,820	$1,634,753
2018	204	64,656	$1,626,068
2019	239	76,139	$2,027,022
2020	235	80,775	$2,341,161
2021	233	73,910	$2,287,073
2022	228	69,226	$2,606,451
2023	230	60,521	$2,450,667
2024	239	63,107	$2,475,761

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	63	504	$1,160,650
2016	58	456	$1,160,688
2017	62	421	$1,135,333
2018	62	430	$1,973,646
2019	61	472	$2,071,610
2020	64	499	$2,431,485
2021	61	525	$1,983,049
2022	76	629	$2,352,028
2023	84	486	$1,861,537
2024	84	622	$2,330,790

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	15	$529

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	41	41	$195
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	120	260	$120
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	190	575	$84
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	86	206	$8
36415	Insertion of needle into vein for collection of blood sample	80	163	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tagrisso	Osimertinib Mesylate	62	1,860	$966,471
Alecensa	Alectinib Hcl	12	360	$219,332
Braftovi	Encorafenib	12	360	$185,499
Mektovi	Binimetinib	11	330	$165,195
Hydrocortisone	Hydrocortisone	59	2,139	$1,952

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	15	$529

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	100	$43,426	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	38	$1,606,351	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kevin B. Kim, M.D.?

Tedicare shows public-source Medicare data for Kevin B. Kim, M.D. (NPI 1851485056), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kevin B. Kim, M.D. have ACO affiliation data?

Kevin B. Kim, M.D. is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604), Main Street Rural Health Sycamore ACO LLC (MSSP, ACO ID A5403), and APA ACO Inc. (REACH, ACO ID D0215).

What billing organization is linked to Kevin B. Kim, M.D.?

Kevin B. Kim, M.D. is linked to SAN FRANCISCO ONCOLOGY ASSOCIATES MEDICAL GROUP INC (billing NPI 1457385379) in the available physician profile data.

Does Kevin B. Kim, M.D. have Open Payments data?

Kevin B. Kim, M.D. has 138 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.